http://www.acc.org/Feed?clinicalTopicID=729dd08e-0a1b-4aa5-bd2a-5e3f31006cb0 Clinical Topic Feed: Acute Heart Failure en /Latest-in-Cardiology/Articles/2026/09/01/01/New-in-Clinical-Guidance An ACC Scientific Statement on managing ASCVD aims to help clinicians overcome the perpetual challenge of balancing the risks of ischemia and bleeding when selecting antiplatelet therapy in this population. 1788265020000 Articles and Stories /Latest-in-Cardiology/Articles/2026/09/01/01/Journal-Wrap The hottest research from various peer-reviewed journals – handpicked weekly by the ACC. 1788264540000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/29/08/48/mon-315am-comboep-esc-2026 Three Hot Line trials from ESC Congress 2026 – ASPIRED, DANISH-CRT, and His-Alternative II – test 14-day ECG monitoring in patients with unexplained syncope, compare cardiac resynchronization therapy (CRT) modalities, and assess targeted left ventricular lead placement at the site of latest electrical activation in patients with heart failure and prolonged QRS. 1788168300000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/29/08/48/mon-guidelines-esc-2026 The European Society of Cardiology (ESC) released three major guideline updates during ESC Congress 2026 related to cardiac rehabilitation, chronic kidney disease (CKD) and heart failure (HF). 1788164580000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/29/08/48/sun-jacc-lbs-esc-2026 Late-breaking science presented at ESC Congress 2026 and simultaneously published in JACC Journals explore the performance of 124I-evuzamitide PET/MRI in patients with established or suspected cardiac amyloidosis (CA), treatment effect of vutrisiran by baseline tafamidis use, and impact of dapagliflozin on congestion in patients hospitalized for heart failure (HF). 1788101460000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/29/08/48/sun-309am-luminara-esc-2026 The addition of AZD5462, an oral once-daily relaxin family peptide receptor 1 agonist, was well tolerated among individuals with well-treated chronic heart failure (HF), based on findings from LUMINARA presented at ESC Congress 2026 and simultaneously published in Circulation. In addition, researchers observed encouraging effects on cardiovascular hemodynamic measures across a wide range of left ventricular ejection fraction (LVEF). 1788082860000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/29/08/48/sun-324am-padn-esc-2026 Pulmonary-artery denervation, in addition to guideline-directed medical therapy, resulted in fewer events of clinical worsening than medical therapy alone in patients with pulmonary hypertension associated with left heart disease and heart failure (HF), based on findings from the PADN-HF-PH trial presented at ESC Congress 2026 and simultaneously published in NEJM. 1788082020000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/29/08/48/sun-253am-combohf-esc-2026 Two major heart failure (HF) studies presented at ESC Congress 2026 delivered neutral results on commonly used therapies, raising important questions about their role in patient management. The H-HeFT trial found that hydralazine plus isosorbide dinitrate (H-ISDN) did not significantly reduce the incidence of death or HF events in patients with HF, while treatment discontinuation rates were high. 1788081720000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/29/08/48/sun-radicalpc2-esc-2026 Uncontrolled modifiable cardiovascular risk factors like suboptimal cholesterol, high blood pressure (BP) and diabetes may help identify those patients with prostate cancer who are more likely to benefit from a referral for routine cardiovascular care, according to findings from the RADICAL PC-2 trial presented at ESC Congress 2026 and simultaneously published in JACC: CardioOncology. 1788081480000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/24/12/30/sat-1215pm-innovation-esc-2026 As digital health moves from promise to practice, several studies presented during a Hot Line Session at ESC Congress 2026 demonstrate how technology can accelerate the implementation of guideline-directed cardiovascular care. From digital strategies that support uptake of SGLT2 inhibitors in patients with heart failure (HF) to remotely delivered exercise programs, targeted outreach to improve statin adherence, and virtual e-health systems for ICD management, these investigations highlight the growing role of technology in optimizing patient care and outcomes. 1788020160000 Articles and Stories